BIOX revenueFY2026$238.28M
- FY YoY
- -17.7%
- 5Y CAGR
- +2.6%
BIOX revenue was $238.28M for fiscal 2026 (ended Jun 30, 2026), down 17.7% from fiscal 2025. Compound annual growth was +2.6% over 5 years. It rose in 6 of the last 8 fiscal years.
Bioceres Crop Solutions Corp. (BIOX) financials
For fiscal 2026 (ended Jun 30, 2026), Bioceres Crop Solutions Corp. reported $238.28M of revenue and -$263.94M of net income.
- Revenue, FY2026
- $238.28M
- Revenue growth, YoY
- -17.7%
- Net income, FY2026
- -$263.94M
- Net margin
- -110.8%
- Free cash flow, FY2026
- $64.96M
- EPS, diluted, FY2026
- -$4.06
- Cash
- $11.24M
- Total debt
- $59.98M
- P/S
- 0.06
- Market cap
- $14.7M
FY2016FY2026
FY2016FY2026
FY2016FY2026
BIOX revenue and earnings growth
BIOX net incomeFY2026-$263.94M
BIOX net income was -$263.94M for fiscal 2026 (ended Jun 30, 2026), compared with -$58.85M in fiscal 2025.
BIOX EPSFY2026-$4.06
BIOX diluted EPS was -$4.06 for fiscal 2026 (ended Jun 30, 2026), compared with -$0.88 in fiscal 2025.
BIOX free cash flowFY2026$64.96M
- FY YoY
- +45.2%
BIOX free cash flow was $64.96M for fiscal 2026 (ended Jun 30, 2026), up 45.2% from fiscal 2025. Fiscal 2026 is the highest of the 10 fiscal years on file.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $238.28M | $289.43M | $420.44M | $420.06M | $334.84M | $209.53M | $173.09M | $160.61M | $133.54M | $41.17M |
| Cost of revenue | $155.10M | $184.38M | $263.04M | $235.46M | $208.36M | $118.64M | $93.58M | $86.96M | $77.09M | $30.60M |
| Gross profit | $83.18M | $105.04M | $157.36M | $184.60M | $126.48M | $90.88M | $79.52M | $73.64M | $56.45M | $10.57M |
| Research and development | $11.03M | $9.46M | $8.37M | $15.35M | $6.95M | $5.62M | $4.20M | $3.69M | $3.95M | $853.9K |
| Selling, general and admin | $71.23M | $93.70M | $96.97M | $113.00M | $77.48M | $47.60M | $38.35M | $39.24M | $35.26M | $8.83M |
| Operating income | -$23.41M | $6.60M | $52.13M | $54.18M | $39.87M | $38.38M | $39.15M | $32.09M | $15.71M | $207.0K |
| Interest expense | $39.92M | $25.08M | $24.81M | $23.79M | $17.93M | $21.24M | $20.88M | $23.41M | $17.19M | $7.15M |
| Pre-tax income | -$75.48M | -$46.52M | $22.26M | $19.11M | $14.06M | $10.53M | $6.44M | -$9.37M | -$25.24M | -$8.04M |
| Income tax | $6.96M | $2.62M | $6.60M | -$1.07M | $17.97M | $14.35M | $2.21M | $6.99M | -$10.93M | -$1.86M |
| Net income | -$263.94M | -$58.85M | $7.29M | $18.78M | -$7.20M | -$6.87M | $3.36M | -$18.37M | -$11.04M | -$5.87M |
| EPS, basic | -$4.06 | -$0.88 | $0.07 | $0.30 | -$0.17 | -$0.18 | $0.09 | -$0.60 | -$0.39 | -$0.21 |
| EPS, diluted | -$4.06 | -$0.88 | $0.07 | $0.30 | -$0.17 | -$0.18 | $0.09 | -$0.60 | -$0.39 | - |
| Diluted shares | 63.6M | 63.2M | 63.5M | 63.2M | 42.3M | 39.2M | 36.4M | 30.5M | 28.1M | 28.1M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.24M | $32.70M | $44.47M | $48.13M | $33.48M | $36.05M | $42.52M | $3.45M | $2.22M | - |
| Receivables | - | - | $207.32M | $158.01M | $111.75M | $88.78M | $73.55M | $59.24M | $52.89M | - |
| Inventory | $46.41M | $87.61M | $125.93M | $140.43M | $126.04M | $61.04M | $29.34M | $27.32M | $19.37M | - |
| Current assets | $215.40M | $308.31M | $408.67M | $397.11M | $297.71M | $211.49M | $164.69M | $98.21M | $85.34M | - |
| Goodwill | $28.55M | $112.16M | $112.16M | $112.16M | $36.07M | $28.75M | $25.53M | $29.80M | $14.44M | - |
| Total assets | $448.23M | $763.65M | $852.55M | $818.06M | $518.22M | $394.59M | $297.56M | $242.47M | $196.64M | - |
| Current liabilities | $270.33M | $337.99M | $329.31M | $298.71M | $222.67M | $168.04M | $130.61M | $116.46M | $118.68M | - |
| Long-term debt | $59.98M | $38.20M | $42.10M | $60.67M | $74.18M | $47.99M | $41.23M | $37.08M | $25.71M | - |
| Total debt | $59.98M | $38.20M | $42.10M | $60.67M | $74.18M | $47.99M | $41.23M | $37.08M | $25.71M | - |
| Total liabilities | $414.17M | $468.43M | $501.17M | $487.56M | $359.92M | $304.30M | $236.81M | $180.37M | $163.51M | - |
| Shareholders' equity | $10.72M | $265.44M | $351.38M | $330.50M | $158.30M | $90.29M | $60.75M | $62.09M | $33.13M | $83.67M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $66.01M | $49.91M | $41.72M | $2.59M | -$17.52M | -$6.21M | $9.32M | $29.69M | $18.39M | -$1.22M |
| Capital expenditures | $1.05M | $5.18M | $8.49M | $11.36M | $3.46M | $2.81M | $1.65M | $2.04M | $2.79M | $608.1K |
| Free cash flow | $64.96M | $44.73M | $33.22M | -$8.77M | -$20.97M | -$9.01M | $7.67M | $27.65M | $15.60M | -$1.83M |
| Investing cash flow | -$5.86M | -$6.13M | -$28.73M | -$25.73M | $2.90M | -$8.31M | -$7.80M | -$3.26M | -$8.22M | -$41.87M |
| Financing cash flow | -$78.71M | -$50.71M | -$10.06M | $32.95M | $14.82M | $7.36M | $33.53M | -$26.95M | -$10.46M | $43.97M |
| Dividends paid | - | $72.1K | $174.8K | $452.1K | - | - | - | - | - | $13.8K |
| Share repurchases | - | $926.9K | $734.4K | $3.00M | - | $3.50M | $30.9K | - | - | - |
| Stock-based compensation | $164.0K | $3.70M | $12.79M | $3.42M | $1.43M | $1.66M | $3.43M | -$102.8K | $30.0K | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -17.7% | -31.2% | 0.1% | 25.4% | 59.8% | 21.0% | 7.8% | 20.3% | - | - |
| Net income growth, YoY | - | - | -61.2% | - | - | - | - | - | - | - |
| EPS growth, YoY | - | - | -77.4% | - | - | - | - | - | - | - |
| Gross margin | 34.9% | 36.3% | 37.4% | 43.9% | 37.8% | 43.4% | 45.9% | 45.9% | 42.3% | 25.7% |
| Operating margin | -9.8% | 2.3% | 12.4% | 12.9% | 11.9% | 18.3% | 22.6% | 20.0% | 11.8% | 0.5% |
| Net margin | -110.8% | -20.3% | 1.7% | 4.5% | -2.2% | -3.3% | 1.9% | -11.4% | -8.3% | -14.2% |
| Free cash flow margin | 27.3% | 15.5% | 7.9% | -2.1% | -6.3% | -4.3% | 4.4% | 17.2% | 11.7% | -4.4% |
| Return on equity | -2462.9% | -22.2% | 2.1% | 5.7% | -4.5% | -7.6% | 5.5% | -29.6% | -33.3% | -7.0% |
| Return on assets | -58.9% | -7.7% | 0.9% | 2.3% | -1.4% | -1.7% | 1.1% | -7.6% | -5.6% | - |
| Current ratio | 0.80 | 0.91 | 1.24 | 1.33 | 1.34 | 1.26 | 1.26 | 0.84 | 0.72 | - |
| Debt to equity | 5.60 | 0.14 | 0.12 | 0.18 | 0.47 | 0.53 | 0.68 | 0.60 | 0.78 | - |
Source: XBRL data Bioceres Crop Solutions Corp. files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BIOX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BIOX | $238.28M | -17.7% | -$263.94M | -110.8% | $14.7M |
| NTR | $26.89B | +3.5% | $2.27B | 8.4% | $33.89B |
| CF | $7.94B | +17.9% | $2.18B | 27.5% | $18.07B |
| MOS | $11.90B | +0.0% | -$1.12B | -9.4% | $7.11B |
| ICL | $7.15B | +4.6% | $226.00M | 3.2% | $6.03B |
| SMG | $3.48B | +4.6% | $73.90M | 2.1% | $3.77B |
| UAN | $659.46M | +7.3% | $106.41M | 16.1% | $1.16B |
| CBUS | $4.35M | -10.3% | -$98.19M | -2258.9% | $90.2M |
| AVD | $510.32M | -3.5% | -$54.58M | -10.7% | $28.4M |
BIOX FAQ
9 questionsWhat is BIOX revenue?
Bioceres Crop Solutions Corp. (BIOX) reported $238.28M of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 17.7% from the year before.Is BIOX profitable?
No. Bioceres Crop Solutions Corp. reported a net loss of $263.94M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does BIOX have?
Bioceres Crop Solutions Corp. reported $11.24M in cash and cash equivalents and $59.98M of debt on its most recent balance sheet in SEC filings.How fast is BIOX revenue growing?
Bioceres Crop Solutions Corp.'s revenue changed -17.7% in fiscal 2026, to $238.28M. Its compound annual growth rate was +2.6% over 5 years.What is BIOX gross margin?
Bioceres Crop Solutions Corp.'s gross profit was $83.18M on $238.28M of revenue for fiscal 2026 (ended Jun 30, 2026), a gross margin of 34.9%.What is BIOX free cash flow?
Bioceres Crop Solutions Corp. generated $64.96M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of $66.01M less capital expenditures.What is BIOX earnings per share?
Diluted earnings per share were -$4.06 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did BIOX last report financial results?
The latest statements here come from Bioceres Crop Solutions Corp.'s 20-F filed on Oct 30, 2026, covering the period ended Jun 30, 2026.Where does this BIOX financial data come from?
Quantisnow builds these statements from the structured XBRL data Bioceres Crop Solutions Corp. files with the SEC. It is provided for information only and is not investment advice.